Purpose in Action: Our Meaningful Engagements & Collaborations

Every research decision has consequences. In healthcare, those consequences affect real patients.

At Venus Medicine Research Centre (VMRC), research is not pursued for visibility. It is pursued for need. Over the past year, the team has focused on two critical areas—antimicrobial resistance (AMR) and nephrology. Both demand careful science, long-term thinking, and strong clinical understanding.

This progress has not happened in isolation. VMRC has worked closely with regulators, research institutions, and global partners to strengthen how findings move from the lab to real-world use. Regulatory approvals, scientific exchanges, and strategic collaborations have all played a role in that journey.

​Each step reflects a clear intention: to develop practical, evidence-based solutions that improve treatment outcomes. This blog looks at how these engagements are shaping meaningful healthcare advances and reinforcing VMRC’s position in global medical research.​

Engagements and Collaborations That Strengthen Research

Research improves when it is questioned, discussed, tested, and shared.

VMRC believes in this and has been a part of some noteworthy scientific meetings, regulatory discussions, and academic exchanges centred on rising drug resistance and responsible antibiotic use. These ensure that ongoing studies address real treatment challenges.

​At the same time, structured partnerships have strengthened research efforts. Joint projects, shared clinical data, and coordinated study planning have improved both the quality and usefulness of the work. ​

‍Driving Regulatory Excellence

Regulatory approval is where scientific data is carefully reviewed.

​This year marked a key milestone for VMRC. VRP-034 received Qualified Infectious Disease Product (QIDP) designation from the USFDA. This status is granted to drug candidates that treat serious infections with limited treatment options.

QIDP designation of VRP-034 offers benefits like priority review and extended market exclusivity in the United States. Most importantly, it highlights the molecule’s relevance in addressing urgent medical needs.

For a therapy focused on antimicrobial resistance, this recognition is significant as it reflects careful development planning and detailed safety assessment.

Aligning with regulatory standards from early stages supports smoother progress and protects patient safety throughout development.

‍Scientific Outreach and Knowledge Sharing

Scientific breakthroughs should not stay confined to internal reports.

​Over the past year, VMRC shared its findings through peer-reviewed journals, including International Journal of Antimicrobial Agents, Antimicrobial Agents and Chemotherapy, and Antibiotics. The published work covered toxicokinetic analysis and approaches to reduce kidney-related side effects during antibiotic therapy.

​When data undergo peer review, it invites scrutiny. That scrutiny strengthens credibility.

​Our team also presented our credible findings at ASM/ESCMID 2024 in Portugal and at Criticare 2024. These meetings brought together clinicians, microbiologists, and critical care specialists managing resistant infections for a collective fight against the increasing crisis.

​Translational Innovation: CRISPR in Action

​Understanding resistant bacteria requires precise tools. VMRC has introduced CRISPR-Cas gene-editing techniques into its antimicrobial studies. This method allows scientists to alter specific bacterial genes and observe how those changes influence drug response.

By doing this, researchers can confirm whether a target is valid before advancing a molecule further. It improves clarity early in development and reduces uncertainty later.

​Gene-level insight also supports smarter drug design. When resistance mechanisms are clearly mapped, therapies can be developed to counter them more effectively.

The objective remains practical — develop treatments that remain reliable even as bacterial resistance evolves.

​Strategic Collaborations: Expanding Global Impact

Fighting antimicrobial resistance is not a one-lab effort. It requires shared science and steady coordination.

Over the past year, VMRC has worked with partners across countries to move key research programs forward. Each collaboration focuses on a defined clinical need.

‍Partnering with INFEX Therapeutics (UK)

​VMRC is working with INFEX Therapeutics on MET-X, a new β-lactamase inhibitor.

Some bacteria produce enzymes that break down antibiotics before they can act. MET-X is designed to block these enzymes.

This could help restore the activity of certain existing antibiotics, especially against extended-spectrum and carbapenem-resistant infections.

​Through this partnership, the molecule is progressing through preclinical testing and early clinical planning with a clear development pathway.

‍​Joint Research with Adjutec Pharma (Norway)

​Along with Adjutec Pharma, VMRC is studying APC-148.

This molecule targets specific bacterial enzymes linked to drug resistance. The goal is to explore a different mechanism of action, which is important as resistance patterns continue to change.

​With their combined capabilities and experience, both teams are working to strengthen the options in the AMR domain.

‍Phase 1 Clinical Trial with Veeda Clinical Research (India)

​VMRC has also partnered with Veeda Clinic Research for a Phase 1 study of VRP-034.

This includes collaboration for early-stage studies focused on safety, dosing, and tolerability. Along with adaptive elements and detailed renal safety monitoring.

Kidney function was closely assessed to ensure patient protection.

The trial reflects a careful, patient-focused clinical approach.

‍Participation in Vivli

VMRC has also been onboarded to Vivli, an international data-sharing platform for clinical research.

Participation supports transparency and responsible data exchange. It also allows researchers to contribute to and learn from broader antimicrobial resistance datasets.

​These collaborations are not symbolic. They are working partnerships. Each one supports stronger research, better data, and progress toward treatments that address real clinical challenges.

​Conclusion: Purpose Realized Through Collaboration

Research only matters if it makes a difference outside the laboratory.

​VMRC’s work in antimicrobial resistance lives upto this as it has moved forward through steady engagement and strong partnerships. Regulatory approvals, published findings, early-stage trials, and collaborative research have all contributed to practical progress.

​By working with partners in India and abroad, VMRC is helping advance new antibiotic strategies and improve safety standards in clinical development.

Each partnership has added depth to the research. Each engagement has strengthened direction. Together, they have helped move ideas closer to treatment reality.

VMRC continues to build on this foundation with its scientific breakthroughs, partnerships and innovative solutions